Psoriasis-associated cutaneous pain: etiology, assessment, impact, and management

References

• Ljosaa TM, Rustoen T, Mörk C. Skin pain and discomfort in psoriasis: an exploratory study of symptom prevalence and characteristics. Acta Derm Venereol. 2010;90:39–45.
   PubMed Web of Science ®Google Scholar
• Nicholson B. Differential diagnosis: nociceptive and neuropathic pain. Am J Manag Care. 2006;12:S256–S262.
   PubMed Web of Science ®Google Scholar
• Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 2014;13:924–935.
   PubMed Web of Science ®Google Scholar
• Chiu IM, Von hehn CA, Woolf CJ. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat Neurosci. 2012;15:1063–1067.
   PubMed Web of Science ®Google Scholar
• Naukkarinen A, Nickoloff BJ, Farber EM. Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J Invest Dermatol. 1989;92:126–129.
   PubMed Web of Science ®Google Scholar
• Eedy DJ, Johnston CF, Shaw C, et al. Neuropeptides in psoriasis: an immunocytochemical and radioimmunoassay study. J Invest Dermatol. 1991;96:434–438.
   PubMed Web of Science ®Google Scholar
• Bull HA, Leslie TA, Chopra S, et al. Expression of nerve growth factor receptors in cutaneous inflammation. Br J Dermatol. 1998;139:776–783.
   PubMed Web of Science ®Google Scholar
• Gupta K, Harvima IT. Mast cell-neural interactions contribute to pain and itch. Immunol Rev. 2018;282:168–187.
   PubMed Web of Science ®Google Scholar
• Steinhoff M, Ständer S, Seeliger S, et al. Modern aspects of cutaneous neurogenic inflammation. Arch Dermatol. 2003;139:1479–1488.
   PubMedGoogle Scholar
• Yang P, Feng J, Luo J, et al. A critical role for TRP channels in the skin. Neurobiology of TRP channels. Boca Fraton, (FL): CRC Press, Taylor & Francis Group; 2018.
   Google Scholar
• Bussa M, Guttilla D, Lucia M, et al. Complex regional pain syndrome type I: a comprehensive review. Acta Anaesthesiol Scand. 2015;59:685–697.
   PubMed Web of Science ®Google Scholar
• Marinus J, Moseley GL, Birklein F, et al. Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol. 2011;10:637–648.
   PubMed Web of Science ®Google Scholar
• Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012;9:302–309.
   PubMed Web of Science ®Google Scholar
• Riol-blanco L, Ordovas-montanes J, Perro M, et al. Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation. Nature. 2014;510:157–161.
   PubMed Web of Science ®Google Scholar
• Patruno C, Napolitano M, Balato N, et al. Psoriasis and skin pain: instrumental and biological evaluations. Acta Derm Venereol. 2015;95:432.
   PubMed Web of Science ®Google Scholar
• Ljosaa TM, Mork C, Stubhaug A, et al. Skin pain and skin discomfort is associated with quality of life in patients with psoriasis. J Eur Acad Dermatol Venereol. 2012;26:29–35.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Zhao Y, Pike J, et al. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity. Dermatol Online J. 2015;21:10.
   Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
   PubMed Web of Science ®Google Scholar
• Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707–713.
   PubMed Web of Science ®Google Scholar
• Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs. 2005;14:798–804.
   PubMed Web of Science ®Google Scholar
• Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011;41:1073–1093.
   PubMed Web of Science ®Google Scholar
• Bushnell DM, Martin ML, Mccarrier K, et al. Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity. J Dermatolog Treat. 2013;24:356–360.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Mathias SD, Schenkel B, et al. Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the psoriasis symptoms and signs diary. J Dermatolog and Dermatolog Surg. 2016;20:19–26.
   Web of Science ®Google Scholar
• Mathias SD, Feldman SR, Crosby RD, et al. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary. J Dermatolog Treat. 2016;27:322–327.
   PubMed Web of Science ®Google Scholar
• Armstrong A, Puig L, Langley R, et al. Validation of psychometric properties and development of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase III clinical trial. J Dermatolog Treat. 2018 [Sep 24];[1–8]. doi: 10.1080/09546634.2017.1364694
   Web of Science ®Google Scholar
• Martin ML, Gordon K, Pinto L, et al. The experience of pain and redness in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2015;26:401–405.
   PubMed Web of Science ®Google Scholar
• Carvalho AB, Garcia JB, Silva TK, et al. Translation and transcultural adaptation of Pain Quality Assessment Scale (PQAS) to Brazilian version. Braz J Anesthesiol. 2016;66:94–104.
   PubMedGoogle Scholar
• Jensen MP, Gammaitoni AR, Olaleye DO, et al. The pain quality assessment scale: assessment of pain quality in carpal tunnel syndrome. J Pain. 2006;7:823–832.
   PubMed Web of Science ®Google Scholar
• Blome C, Gosau R, Radtke MA, et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res. 2016;308:69–78.
   PubMed Web of Science ®Google Scholar
• Korman NJ, Zhao Y, Li Y, et al. Clinical symptoms and self-reported disease severity among patients with psoriasis - implications for psoriasis management. J Dermatolog Treat. 2015;26:514–519.
   PubMed Web of Science ®Google Scholar
• Ljosaa TM, Stubhaug A, Mork C, et al. Improvement in psoriasis area and severity index score predicts improvement in skin pain over time in patients with psoriasis. Acta Derm Venereol. 2013;93:330–334.
   PubMed Web of Science ®Google Scholar
• Sampogna F, Gisondi P, Melchi CF, et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol. 2004;151:594–599.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Jo SJ, Naldi L, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179(1):173–181.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum L, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407.
   PubMed Web of Science ®Google Scholar
• Carneiro C, Chaves M, Verardino G, et al. Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. CCID. 2017;10:155–163.
   Google Scholar
• Lewis-Beck C, Abouzaid S, Xie L, et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199–205.
   PubMed Web of Science ®Google Scholar
• Bilac C, Ermertcan AT, Bilac DB, et al. The relationship between symptoms and patient characteristics among psoriasis patients. Indian J Dermatol Venereol Leprol. 2009;75:551.
   PubMed Web of Science ®Google Scholar
• Jensen AM, Lladó MB, Skov L, et al. Calcipotriol inhibits the proliferation of hyperproliferative CD29 positive keratinocytes in psoriatic epidermis in the absence of an effect on the function and number of antigen-presenting cells. Br J Dermatol. 1998;139:984–991.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Humbert P, Nicolas JF, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol. 2003;148:326–333.
   PubMed Web of Science ®Google Scholar
• Sobell JM, Foley P, Toth D, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96:514–520.
   PubMed Web of Science ®Google Scholar
• Bagel J, Nelson E, Keegan BRA, et al. B combination therapy for treating moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2017;16:957–962.
   PubMed Web of Science ®Google Scholar
• Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272–284.
   PubMed Web of Science ®Google Scholar
• Strober B, Sigurgeirsson B, Popp G, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016;55:401–407.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Green L, Kimball AB, et al. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat. 2017;28:716–721.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Sullivan J, Van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76:70–80.
   PubMed Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Kimball AB, et al. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. J Eur Acad Dermatol Venereol. 2018;32(9):1515–1522.
   PubMed Web of Science ®Google Scholar
• Bernstein JE, Parish LC, Rapaport M, et al. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol. 1986;15:504–507.
   PubMed Web of Science ®Google Scholar
• Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol. 1994;46:517–522.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Sanyal M, Weltman H, et al. K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol. 2004;122:812–819.
   PubMed Web of Science ®Google Scholar
• Levine JD, Alessandri-haber N. TRP channels: targets for the relief of pain. Biochim Biophys Acta. 2007;1772:989–1003.
   PubMed Web of Science ®Google Scholar